Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
University of Washington
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00880178CT.gov Plaque Inflammation and Dysfunctional HDL in AIM-HIGH | — | Completed | — | — | — |
NCT00461630CT.gov Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE | — | Completed | — | — | — |
NCT00120289CT.gov Niacin Plus Statin to Prevent Vascular Events | — | Terminated | — | — | — |
NCT00079638CT.gov Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Coronary Artery Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niacin (this asset) | University of Washington | Approved | BB · 68 |
| Aspirin | Rajaie Cardiovascular Medical and Research Center | P4 | BBB |
| Ezetimibe | Canadian Collaborative Research Network | P4 | BBB |
| Rivaroxaban | Sheffield Teaching Hospitals NHS Foundation Trust | P4 | BBB |
| Ranolazine | OBS Pakistan | P4 | BBB |
| Simvastatin | University of Washington | P4 | BBB |
| Pitavastatin | Yokohama City University Medical Center | P4 | BBB |
| Clopidogrel | Beijing Tiantan Hospital | P4 | BB |
| Rosuvastatin | Canadian Collaborative Research Network | P4 | BB |
+40 more in the Coronary Artery Disorder cohort
Other indications for Niacin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Abdominal Obesity-Metabolic Syndrome | — | P4 | BB · 68 |
| Inherited Lipid Metabolism Disorder | — | P4 | BB · 68 |
| Stroke Disorder | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Niacin in Coronary Artery Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/niacin-coronary-artery-disorder-18702
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →